European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

by Marie Weil
January 25, 2023
A A
Share on LinkedinShare on Twitter
  • Sandoz plans to acquire worldwide product rights for Mycamine®(micafungin sodium) from Astellas
  • Acquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolio
  • Addition of Mycamine®will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies 

Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas.

Closing is anticipated in the course of H1, 2023, subject to standard conditions and regulatory approvals.

Astellas reported Mycamine® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2022. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.

Sandoz CEO Richard Saynor said: “Acquiring this leading and respected global brand will significantly reinforce the Sandoz global hospital offering, as well as complement our existing global leadership position in generic antibiotics.”

He added: “This will also be an important addition to our growing portfolio of anti-infective therapies aimed at combatting the spread of antimicrobial resistance, by providing the right drug to the right patient at the right time.”

Sandoz Anti-Infectives global medical lead Nicholas Adomakoh said: “Modern medicine is increasingly characterized by the need for complex interventions involving highly vulnerable patients. This welcome and timely portfolio addition will allow us to respond even better to the needs of patients and clinicians across the healthcare continuum.”

Mycamine®   is a leading global echinocandin, one of three major classes of antifungal agents, with a global patient base of well over two million. It   is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in hematology and oncology patients, and widely used in organ transplants.

Mycamine®   is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.

Tags: < Invest

Related Industries

Health

Siemens Healthineers presents mammography system with groundbreaking new imaging technology

September 28, 2023
Health

Dr. Jost Reinhard appointed new head of Investor Relations at Bayer

September 20, 2023
Health

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

August 29, 2023
Health

Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing / Open Innovation

August 23, 2023
Health

Innovative research for malaria control driven by three collaborating parties: Swiss TPH, BASF and Promega

August 18, 2023
Health

SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities

August 15, 2023

Menzies Aviation renews Jazeera Airways contract in Kuwait and wins new business in Europe and Pakistan

September 6, 2023

...

Bayer to invest EUR 220 million in new R&D facility at its Monheim site

September 1, 2023

...

Henkel unveils its first world-class Battery Engineering Center in its Inspiration Center Duesseldorf

September 5, 2023

...

Getting heavy-duty vehicles in gear for net-zero

September 5, 2023

...

ABB invests in strategic partnership with clean energy start-up to offer end-to-end wind energy portfolio

September 7, 2023

...

Schneider Electric appoints Gwenaelle Avice-Huet as Executive Vice-President Europe Operations

September 8, 2023

...

ABN AMRO intends to appoint Ferdinand Vaandrager as Chief Financial Officer

September 6, 2023

...

Siemens Healthineers presents mammography system with groundbreaking new imaging technology

September 28, 2023

...

Huawei Ireland launches new 2023 STEM programme with global prize fund of $100K

September 13, 2023

...

Mobileye and Valeo Launch a Partnership for World-Class Imaging Radars

September 5, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist